Leading brokers name 3 ASX shares to buy today

Here's why brokers rate these ASX shares as buys…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Business man marking buy on board and underlining it.

Image Source: Getty Images

Appen Ltd (ASX: APX)

According to a note out of Citi, its analysts have retained their buy rating and $17.10 price target on this artificial intelligence data services company's shares. Citi is sticking with Appen despite news that Amazon has launched a new SageMaker Ground Truth Plus service that uses an expert workforce to deliver high-quality training datasets faster. The broker believes that while competition in the Enterprise space may increase, competition with Appen's major technology customers shouldn't be impacted. The Appen share price is trading at $9.21 on Monday afternoon.

Australia and New Zealand Banking GrpLtd (ASX: ANZ)

A note out of Morgans reveals that its analysts have retained their add rating and $31.00 price target on this banking giant's shares. Morgans remains positive on the banking sector as a whole and believes there is potential for further capital management and generous dividends in the near term. Its analysts also expect rising interest rates to be supportive of earnings growth in the coming years. The ANZ share price is fetching $26.87 today.

ResMed Inc. (ASX: RMD)

Analysts at Macquarie have upgraded this medical device company's shares to an outperform rating with a $39.00 price target. While Macquarie acknowledges that supply chain issues are putting pressure on near term device supply, its analysts remain positive. This is due to an expected increase in industry volume growth from 2023 and market share gains for ResMed. Macquarie believes this will support revenue and earnings growth ahead of current analyst consensus estimates. The ResMed share price is trading at $36.29 on Monday.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Appen Ltd. The Motley Fool Australia owns shares of and has recommended Appen Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

three excited doctors with hands in the air
Broker Notes

Buy, hold, sell: Super Retail, APA, Sonic Healthcare shares

As earnings season continues, brokers have issued new ratings on these 3 ASX 200 shares.

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

3 ASX shares UBS says will return better than 36%

These three companies have big things ahead, according to UBS.

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

Up more than 200% over a year, could this ASX lithium company double again?

The potential upside on these shares might surprise.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Buy, hold, sell: Fortescue, Northern Star, and Megaport shares

Morgans has updated its views on these shares.

Read more »

Man with his hand on his face reading a letter with bad news in it.
Broker Notes

Why were Goodman shares just downgraded?

Bell Potter has cut its rating on the industrial property company.

Read more »

Cheerful smiling businesswoman sitting on a chair and typing business report on a laptop keyboard.
Broker Notes

Broker puts fresh buy ratings and tips 36% upside for these earnings results winners 

These two shares have received upgraded outlooks.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

Why were Telix shares just downgraded?

Bell Potter has become less bullish on this biotech.

Read more »

a man with his back facing the camera sits at a computer displaying a screen of code with an electric power contraption on the desk near him as he sits in concentration while appearing to mine cryptocurrency.
Broker Notes

Are Fortescue shares in the buy zone after its results?

Bell Potter has given its verdict on this mining giant's shares.

Read more »